

Basal characteristics of the prospective Spanish Immunotherapy Registry of Cardiovascular Toxicity: SIR-CVT

Eduardo Zatarain Nicolás¹, Sara Pérez Ramírez², Javier de Castro Carpeño³, Ana Martín García⁴, Edel del Barco⁵, Marinela Chaparro Muñoz⁶; Juan Antonio Virizuela Echaburu⁷; Teresa Lozano Palencia⁸, Natividad Martínez-Banaclocha⁹; Dolores Mesa Rubio¹⁰, Juan de la Haba¹¹, María Amparo Martínez Monzonís¹², Santiago Aguin Losada¹³, M Carmen Gómez-Rubin¹⁴, Patricia Cortez-Castedo¹⁵, Eduardo Teran Brage⁵, Rocio Eiros Bachiller⁴; Clara Sanchez Pablo⁴; Leticia Nieto Garcia⁴; Andrea Gomez Sanchez⁴; Ivan Marquez Rodas²; Borja Ibañez¹⁶; Pilar Martín¹⁶ and Teresa López-Fernández¹⁷ on behalf of the SIR-CVT investigators.

1. Cardiology Department, Gregorio Marañón University Hospital, IIBSGM, Complutense University, CIBER-CV (ISCIII), Madrid, Spain. 2. Medical Oncology Department, Gregorio Marañón University Hospital, Madrid, Spain. 3. Medical Oncology Department, La Paz University Hospital, Madrid, Spain. 4. Cardiology Department, University Hospital of Salamanca, IBSAL, USAL, CIBER-CV (ISCIII), Salamanca, Spain. 5. Medical Oncology Department, University Hospital of Salamanca, Salamanca, Spain. 6. Cardiology department, Virgen de la Macarena University Hospital, Sevilla, Spain. 7. Oncology department, Virgen de la Macarena University Hospital, Sevilla, Spain. 8. Cardiology department, Dr. Balmis General University Hospital, Alicante, Spain. 9. Oncology Department, Dr. Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain. 10. Cardiology Department, Reina Sofia University Hospital and Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), Córdoba, Spain. 11. Oncology Department, Reina Sofia University Hospital and Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), Córdoba, Spain. 12. Cardiology Department, University Hospital Complex of Santiago de Compostela, A Coruña, Spain. 13. Hospital Complex Ruber Juan Bravo, Madrid, Spain. 14. Hospital Complex Ruber Juan Bravo, Madrid, Spain. 15. Hospital Complex Ruber Juan Bravo, Madrid, Spain. 16. National Centre of Cardiovascular Research (CNIC), CIBER-CV (ISCIII), Madrid, Spain. 17. Cardiology Department, La Paz University Hospital. IdiPAZ Research Institute. Madrid. Spain






Table 1. Basal cancer characteristics

Cancer type	
Renal n(%)	8 (16.7)
Urothelial n(%)	6 (12.5)
Lung (non schamous) n(%)	17 (35.4)
Lung (schamous) n(%)	9 (18.8)
Lung (Small-cell) n(%)	1 (2.1)
Melanoma n(%)	7 (14.6)
Other n(%)	5 (9.4)
Treatment setting	
Metastasic n(%)	38 (71.6)
Adjuvant n(%)	8 (16.7)
Neoadjuvant n(%)	2 (4.2)
ICI treatment	
Pembrolizumab n(%)	24 (45.2)
Nivolumab (monotherapy) n(%)	6 (11.3)
Ipilimumab+Nivolumab n(%)	5 (9.4)
Atezolizumab n(%)	9 (16.9)
Otros n(%)	10 (18.8)
Any concurrent chemotherapy n(%)	33 (68.8)
Concurrent radiation n(%)	6 (12.8)



Conclusion: Baseline CV morbidity is high in a real-world cohort of patients with cancer referred to ICI therapy. The rise in NTproBNP levels can reflect older age and myocardial fibrosis at baseline.